Pedersen, Maggie Fick and Bhanvi Satija COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year profit and sales forecasts on Wednesday as growth slows, but investors saw some cheer in a better-than-expected Medicare pricing deal that helped temper a share price slide.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk trimmed its full-year forecasts on Wednesday as sales growth of its blockbuster obesity drugs slows, leaving investors worried the firm is losing ground to U.

Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by the company to support the drug's approval in obesity, the study led to greater improvements in risk factors such as C-reactive protein and serum triglycerides.

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these generic versions are more affordable than the branded drugs. The company also recently rolled out compounded GLP-1 microdosing treatment plans.

Telehealth company Hims & Hers Health Inc. said late Monday it is in “active discussions” with Denmark’s Novo Nordisk A/S to make Wegovy available on its platform.

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy’s benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose.

After a company-wide restructuring costing some DKK 9 billion ($1.38 billion), Novo’s path to success lies in its ability to create the next healthcare-altering drug. This, says Novo CFO Karsten Munk Knudsen, will be the “silver bullet” to defending key markets from competitors.